Target intelligence / Profile preview

Tumor-associated antigen peptide-MHC complex (pMHC)

Target
pMHC
Molecular classification
Other
01

Overview

Tumor-associated antigens presented by MHC class I/II (peptide-MHC or pMHC complexes) represent a crucial class of therapeutic targets in cancer immunotherapy. Under physiological conditions, intracellular proteins are degraded by the proteasome into short peptide fragments, which are then loaded onto major histocompatibility complex (MHC) class I or II molecules for presentation on the cell surface. In malignant cells, aberrantly expressed, mutated, or overexpressed proteins (such as cancer-testis antigens, neoantigens, or lineage-specific proteins) are presented as tumor-associated antigens (TAAs) within the MHC groove. This presentation provides a 'window' into the intracellular proteome, allowing the adaptive immune system to detect and eliminate cancer cells.

Therapeutic strategies targeting these pMHC complexes include T-cell receptor-engineered T-cell (TCR-T) therapies and soluble bispecific biologics, such as immune-mobilizing monoclonal T-cell receptors against cancer (ImmTACs) and T-cell receptor-mimic (TCRm) antibodies. These modalities bypass the limitations of traditional chimeric antigen receptor (CAR) therapies, which are restricted to cell-surface proteins, thereby vastly expanding the pool of targetable tumor antigens. However, targeting pMHC complexes presents unique challenges, including strict HLA restriction (requiring patient matching to specific HLA alleles), potential for severe on-target, off-tumor toxicities, and the risk of lethal cross-reactivity with similar self-peptides presented on healthy tissues.

Other names
Tumor-associated antigens presented by MHC class I/IIPeptide-MHC complexpMHC complexPeptide-HLA complexpHLA complexTumor-associated antigen presented by major histocompatibility complex
02

Mechanism of action

T-cell redirection via bispecific T-cell engagers (ImmTACs) or adoptive cell transfer of TCR-engineered T-cells (TCR-T) to recognize specific peptide-MHC complexes and induce tumor cell lysis.

03

Biological functions

Immune responseOther
04

Disease associations

Cancer
05

Safety considerations

Cytokine release syndrome (CRS)On-target, off-tumor toxicityCross-reactivity with self-peptidesProlonged cytopeniaNeurotoxicityHLA restriction
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

HLA-A*02:01HLA-A*02:02HLA-A*02:03HLA-A*02:06gp100 expressionMAGE-A4 expressionPRAME expressionNY-ESO-1 expression

Beyond the preview

Go deeper on Tumor-associated antigen peptide-MHC complex (pMHC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor-associated antigen peptide-MHC complex (pMHC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call